The Emergence of CAR T-Cell Therapy in India: Analyzing Affordability, Clinical Trial Momentum, and the Drive for Indigenous Innovation in Cancer Immunotherapy
The India CAR T-Cell Therapy Market is at an inflection point, transitioning from a purely clinical research landscape to a burgeoning commercial sector, despite facing unique socio-economic and infrastructural challenges. The fundamental driver is the high burden of hematological cancers and the clear, unmet medical need for advanced therapies among patients who have relapsed after standard treatments. While global products have set the benchmark, the market's true potential is being unlocked by a strong push for indigenous CAR T-cell development led by Indian research institutions and biotech start-ups. These local efforts are specifically aimed at creating cost-effective versions of the therapy, which is critical for a price-sensitive market like India where affordability dictates accessibility for the majority of the population. The government's focus on promoting biotechnology and the…